Last reviewed · How we verify
prostaglandin I2 analogue
At a glance
| Generic name | prostaglandin I2 analogue |
|---|---|
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) (PHASE2)
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) (PHASE2)
- Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD) (NA)
- Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension (EARLY_PHASE1)
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) (PHASE3)
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PHASE2)
- Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prostaglandin I2 analogue CI brief — competitive landscape report
- prostaglandin I2 analogue updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI